Prosecution Insights
Last updated: October 26, 2026

Quincy Andre Mckoy, USPTO Patent Examiner

Listed by the USPTO as MCKOY, QUINCY ANDRE

Tech Center 1600 • Art Units: 1625 1626 1682

This examiner grants 68% of resolved cases

Analysis

MCKOY, QUINCY ANDRE is assigned to Tech Center 1600 and art unit 1625. The profile covers 114 resolved cases, with an allowance rate of 68.4%. The median time to allowance is 1190 days, indicating that allowance generally follows a sustained examination process. The resolved-case base provides useful direction, but matter-specific claim scope remains important.

The interview lift is 39.8%, linking interviews with a substantial improvement in allowance outcomes. Practitioners may use interviews to explain technical distinctions, focus amendments, and determine whether a written response can be narrowed effectively. The leading companies are Hoffmann-La Roche Inc., Boehringer Ingelheim International GmbH, and Genentech Inc. The leading firms are MARSHALL, GERSTEIN & BORUN LLP, BakerHostetler, and Casimir Jones, S.C.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

68.4%
Allow Rate
+8.4% vs TC avg
146
Total Applications
+39.8%
Interview Lift
1190
Avg Prosecution Days
Based on 114 resolved cases, 2023–2026

Rejection Statute Breakdown

3.1%
§101 Eligibility
18.4%
§102 Novelty
36.0%
§103 Obviousness
27.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18789815 PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN Non-Final OA Boehringer Ingelheim International GmbH
18547096 INSECT AND ACARINA PEST CONTROL Final Rejection SYNGENTA CROP PROTECTION AG
18684143 ACID CERAMIDASE INHIBITORS AND USES THEREOF Final Rejection The Regents of the University of California
18281737 COMPOSITIONS AND METHODS FOR INHIBITING PLpro PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-CoV-2 INFECTION Final Rejection Arizona Board of Regents on Behalf of the University of Arizona

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Quincy Andre Mckoy's allowance rate?

68.4% of resolved applications examined by Quincy Andre Mckoy were allowed (114 resolved cases), compared with 51.6% across Art Unit 1625 over the last five years.

Does an interview help with examiner Quincy Andre Mckoy?

This examiner's interview lift is +39.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Quincy Andre Mckoy take to allow a patent?

Applications allowed by Quincy Andre Mckoy took 1,190 days on average from filing to allowance.

Which art unit does examiner Quincy Andre Mckoy work in?

Quincy Andre Mckoy examines applications in Art Unit 1625 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month